Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents

DOI: 10.1634/theoncologist.2016-0055

Keywords: Programmed cell death 1 receptor, Nivolumab, Pembrolizumab, Drug-related side effects and adverse reactions, Melanoma

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text